![[Adobe Stock]](https://sp-ao.shortpixel.ai/client/to_webp,q_glossy,ret_img,w_750,h_375/https://www.psypost.org/wp-content/uploads/2021/12/psychedelic-psilocybin-magic-mushrooms-750x375.jpg)
Scientists have started to investigate whether a compound found in magic mushrooms, psilocybin, could play a role in combating the effects of diabetes. According to their preliminary research, published in the journal Genes, psilocybin might help prevent the loss of critical insulin-producing cells in the pancreas.
Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. In recent years, its therapeutic potential has begun to be recognized, particularly for mental health conditions. The rationale for this study, however, stems from psilocybin’s interaction with serotonin receptors in the brain, which are also present in the pancreas. These receptors play a crucial role in regulating insulin production and release, a process that is often disrupted in diabetes.
Diabetes is a chronic metabolic disorder characterized by high blood sugar levels, which over time can lead to serious health complications. The global prevalence of diabetes is rising at an alarming rate, with estimates suggesting that 783 million people could be affected by 2045. Type II diabetes, the most common form of the disease, is closely linked to obesity and a sedentary lifestyle.
“Diabetes and metabolic syndrome plague society and we were looking for various ways to contribute to the fight against those conditions,” said study author Igor Kovalchuk, a professor of biological sciences at the University of Lethbridge. “Since microdosing with mushrooms could become one of the treatment options for various diseases, we wanted to test whether its active ingredient, psilocybin, would also have anti-diabetic effects.”
Central to the development of diabetes is the dysfunction of pancreatic β-cells, the cells responsible for producing insulin. When these cells are damaged or lost, the body’s ability to regulate blood sugar levels is compromised.
In their new study, the researchers investigated the effects of psilocybin on pancreatic β-cells exposed to high glucose and high lipid conditions, a scenario that mimics the metabolic stress observed in diabetes. They used a rat insulinoma cell line, a model known for its relevance to human β-cell function, to conduct their experiments.
Cultured in a nutrient-rich medium, the cells were treated with a specific concentration of psilocybin, chosen based on preliminary results that suggested its optimal efficacy. Following psilocybin treatment, the cells were exposed to high glucose and high lipid conditions, designed to induce the stress and damage typically observed in the pancreatic β-cells of individuals with diabetes.
The researchers found that cells treated with psilocybin demonstrated markedly better viability compared to those not receiving the treatment. This result suggests that psilocybin has a protective effect on β-cells, helping to mitigate the detrimental impact of the metabolic stress associated with diabetes.
Further analysis provided insights into the mechanisms behind psilocybin’s protective effects. Through Western blot analysis, the study found that psilocybin treatment led to a decrease in the levels of several key apoptotic biomarkers in β-cells challenged with high glucose and lipid levels. Apoptosis, or programmed cell death, plays a significant role in the loss of β-cells in diabetes, and the ability of psilocybin to reduce markers associated with this process indicates its potential to preserve β-cell mass in diabetic conditions.
“We did not expect psilocybin to work so well on pancreas cells,” Kovalchuk remarked.
Psilocybin also appeared to impact the expression of genes related to β-cell dedifferentiation. Dedifferentiation refers to the process by which mature, insulin-producing β-cells revert to a more primitive state and lose their ability to produce insulin effectively.
The findings provide preliminary evidence that “microdosing with magic mushrooms will likely have positive effect for people with metabolic syndrome (pre-diabetes) and diabetes,” Kovalchuk told PsyPost.
Interestingly, despite these positive effects on cell survival and dedifferentiation, the researchers observed that psilocybin did not significantly improve impaired glucose-stimulated insulin secretion (GSIS) under high glucose and lipid conditions. This finding indicates that while psilocybin can protect β-cells from death and dedifferentiation, it may not directly enhance their functional response to glucose in the context of metabolic syndrome or diabetes.
The study, while pioneering in its exploration of psilocybin’s potential therapeutic effects on pancreatic β-cells in the context of diabetes, includes several limitations that pave the way for future research directions. Firstly, the research was conducted using a rat insulinoma cell line, which, although valuable for initial investigations, does not fully replicate the complex physiological and metabolic interactions occurring in living organisms.
“We need to perform this study on animals to be sure it works as well as it does in vitro,” Kovalchuk noted.
In addition, the study focused on the effects of psilocybin under specific conditions of high glucose and lipid-induced stress, representing only one aspect of diabetes pathology. Diabetes is a multifactorial disease with a wide range of pathophysiological features, including insulin resistance, inflammation, and autoimmune components in the case of Type 1 diabetes.
Ultimately, the researchers hope to examine whether psilocybin can be of benefit to human diabetes patients, Kovalchuk said. “We are always looking for more natural/traditional/holistic ways to treat diseases.”
The study, “The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation,” was authored by Esmaeel Ghasemi Gojani, Bo Wang, Dong-Ping Li, Olga Kovalchuk, and Igor Kovalchuk.
